Safety Study of AMI MultiStem® to Treat Heart Attacks
A Phase I, Multicenter, Dose-Escalation Trial Evaluating the Safety of Allogeneic AMI MultiStem® in Patients With Acute Myocardial Infarction
Sponsor: Angiotech Pharmaceuticals
Listed as NCT00677222, this PHASE1 trial focuses on Acute Myocardial Infarction and remains completed. Sponsored by Angiotech Pharmaceuticals, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1
-
Oct 2024 — Jun 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Angiotech Pharmaceuticals
- Healios K.K.
- PPD Development, LP
For direct contact, visit the study record on ClinicalTrials.gov .